ESMO ECCO 2015

Area: Oncology

Location: Vienna, Austria

Date: September 25 to September 29

Description:

European Cancer Congress.


Search in Scientific Content:
Date
Filters:

New analysis from EUROCARE 5

Presenter: Milena Sant
Oncology : Lymphoma
Nivolumab
4:14

Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma

Presenter: Padmanee Sharma
Oncology : Lymphoma
Cabozantin
6:18

Cabozantinib vs. everolimus in patients with advanced renal cell carcinoma: results of a randomized phase 3 trial (METEOR)

Presenter: Toni K. Choueiri
Oncology : Lymphoma
Tumor grow
16:04

Tumor growth over time: analysis of data from the LUME-Lung 1 trial

Presenter: Anders Mellengard
Oncology : Lymphoma
Understand
14:58

Understanding Physician Prescribing Behavior in Second-Line Adenocarcinoma of the Lung

Presenter: Nicolas Girard
Oncology : Lymphoma
Genomic ch
9:01

Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets

Presenter: Priscilla K. Brastianos
Oncology : Lymphoma
Efficacy a
8:23

Efficacy and Safety Results from the Placebo-Controlled, Double-blind, Multicenter, Ph

Presenter: James C. Yao
Oncology : Lymphoma
Lu-177-Dot
8:31

Lu-177-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumours: Results of the Phase III NETTER-1 Trial

Presenter: Philippe Ruszniewski
Oncology : Lymphoma
Two-year e
7:40

Two-year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib + trametinib vs. vemurafenib as first-line ther

Presenter: Caroline Robert
Oncology : Lymphoma
The effect
4:59

The effect of aspirin as additional treatment in patients with a gastrointestinal malignancy

Presenter: Martine Frouws
Oncology : Lymphoma
Ovarian su
7:07

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients.

Presenter: Matteo Lambertini
Oncology : Lymphoma
Phase I su
5:08

Phase I sudy of a DLL3-targeted antibody drug conjugate (ADC), rovalpituzumab tesirine, in patients with relapsed and refractory small cell lung cancer (

Presenter: Catherine Pietanza
Oncology : Lymphoma
Social dep
5:01

Social deprivation & gender affect incidence of Hodgkin lymphoma in children & young adults

Presenter: Richard J.Q. McNally
Oncology : Lymphoma
Outcome of
6:24

Outcome of 129 children after antenatal exposure to cancer treatment: Results of a case-control study from the International Network on Cancer, Infertility and Pregnancy

Presenter: Frederic Amant
Oncology : Lymphoma
The novelt
4:22

The novelties of ECCO2015 and the impaired cancer treatment access in CE Europe

Presenter: Martine Piccart
Oncology : Lymphoma
Tumor grow
7:54

Tumor growth over time in patients with advanced NSCLC Treated with nintedanib plus docetaxel vs. docetaxel: Analysis of data from the LUME-Lung 1 study

Presenter: Anders Mellengard
Oncology : Lymphoma
Renal cell
7:43

Renal cell carcinoma as new target of immunotherapy: the CheckMate 025 study

Presenter: Padmanee Sharma
Oncology : Lymphoma
Highlights
21:00

Highlights in targeted therapy and immunotherapy at ECCO2015

Presenter: Christoph Zielinski
Oncology : Lymphoma
Launch of
8:28

Launch of the European Society for Paediatric Oncology strategic cancer plan for children and adolescents

Presenter: Gilles Vassal
Oncology : Lymphoma
Reflects o
5:20

Reflects on the findings and suggestions of the radiotherapy commission

Presenter: Philip Poortmans
Oncology : Lymphoma
Expanding
8:00

Expanding global access to radiotherapy: myths and facts

Presenter: Rifat Atun
Oncology : Lymphoma
The signif
9:35

The significance of NETTER-1 trial in the world-wide approval of peptide receptor radionuclide therapy for the treatment of NETs

Presenter: Philippe Ruszniewski
Oncology : Lymphoma
Role of im
5:54

Role of immunotherapy in renal cell cancer

Presenter: Viktor Grünwald
Oncology : Lymphoma
Treatment
11:39

Treatment options of neuroendocrine tumors with focus on the NETTER-1 Trial

Presenter: Philippe Ruszniewski
Oncology : Lymphoma
Highlights
9:41

Highlights of ECCO2015 congress as well as the future role of ESMO and ECCO

Presenter: Rolf Stahel
Oncology : Lymphoma
Use of asp
5:59

Use of aspirin after diagnosis improves survival in many gastrointestinal cancer types according to retrospective, registry data

Presenter: Martine Frouws
Oncology : Lymphoma
Shares her
10:05

Shares her insight on the importance of modern cancer research for humanity, and talks about the most significant developments in cancer science

Presenter: Margaret Foti
Oncology : Lymphoma
The role o
6:19

The role of immunotherapy and checkpoint inhibitors in the treatment of genitourinary malignancies: new results presented at ECCO2015

Presenter: Ignacio Duran
Oncology : Lymphoma
Evaluation
7:18

Evaluation of ovarian suppression with LHRH agonists during chemotherapy as an option to preserve ovarian function and fertility in breast cancer patients

Presenter: Matteo Lambertini
Oncology : Lymphoma
Should can
6:50

Should cancer diagnosis during pregnancy lead to treatment delay or pregnancy termination?

Presenter: Frederic Amant
Oncology : Lymphoma

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia

ESMO 2014

2014-09-26 - 2014-09-30
Madrid, Spain